000			03007cam a2200349 a 4500
003			EG-GiCUC
005			20250223032842.0
008			211104s2021 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.11.20.Ph.D.2021.Mo.R
100	0		_aMohammed Said Hassan
245	1	0	_aRituximab versus azathioprine therapy in neuromyelitis optica spectrum disorder patients / _cMohammed Said Hassan ; Supervised Sherif Hamdy , Nevin Moheildin , Ahmed Nemr
246	1	5	_aعقار ريتوكسيماب مقابل عقار الأزاثيوبرين فى مرضى التهاب النخاع العصبى الطيفى البصرى
260			_aCairo : _bMohammed Said Hassan , _c2021
300			_a164 P . : _bcharts ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Neuro Surgery
520			_aBackground: Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system characterized by severe attacks of optic neuritis and longitudinally extensive transverse myelitis. Recently, the demonstration of a pathogenic role for the anti{u2013}aquaporin 4 (AQP4) antibody in NMO has marked a major advance in the understanding o the disease Aim of work: The aim of this study was to report the results of rituximab treatment in NMO spectrum disorders (NMOSDs) Patients and Methods: This was a retrospective observational study conducted on 74 Egyptian patients with NMOSDs. The patients{u2018} data were recruited from patient records in multiple sclerosis (MS) clinics, Neurology Departments, El- Maady Military Hospital (records from 2005) and Cairo University hospitals (Kasr Al-Ainy MS Clinic) (records from 2013) including their full medical history, general and neurological examination, MRI brain and spinal cord results, and laboratory investigation including: immune assays and AQP- 4antibody testing as per MS and MS mimics sheet of Kasr Al-Ainy MS clinic.Results: The study included 74 Patients with NMOSD according to criteria of Wagnerchuck 2015. Both sero-positive and sero-negative anti-aquaporin-4 (AQP-4) antibodies patients were included in the study. The patients were divided into three groups: group 1 (RTX group) included 25 patient; group 2 (AZA group) included 32 patients, and group 3 (Switchers) included 17 patients. Conclusion: our findings suggest that RTX is more effective and safe than AZA in NMO-SD patients. Further studies with larger sample sizes and longer duration of follow-up are reqired to confirm these findings in our country
530			_aIssued also as CD
653		4	_aAzathioprine
653		4	_aNeuromyelitis
653		4	_aRituximab
700	0		_aAhmed Nemr , _eSupervisor
700	0		_aNevin Moheildin , _eSupervisor
700	0		_aSherif Hamdy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aAmira _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c82978 _d82978